IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
IO Biotech (IOBT) presented new preclinical data for its novel peptide vaccine IO170 at the AACR-IO conference. The vaccine targets Transforming Growth Factor Beta (TGF-β), a key immune-suppressive factor in solid tumors. Unlike existing approaches that inhibit TGF-β systemically, IO170 selectively modulates TGF-β activity using IO Biotech's proprietary T-win® platform.
The preclinical studies demonstrated that IO170 significantly reduced tumor growth in pancreatic adenocarcinoma and prostate cancer models. The vaccine induced robust immune responses and reshaped the tumor microenvironment (TME) without causing systemic toxicity or adverse off-target effects. The company is preparing for an Investigational New Drug Application (IND) submission to FDA for IO170.
IO Biotech (IOBT) ha presentato nuovi dati preclinici per il suo innovativo vaccino peptidico IO170 durante la conferenza AACR-IO. Il vaccino mira al Fattore di Crescita Trasformante Beta (TGF-β), un fattore chiave di immunosoppressione nei tumori solidi. A differenza degli approcci esistenti che inibiscono il TGF-β in modo sistemico, IO170 modula selettivamente l'attività del TGF-β utilizzando la piattaforma proprietaria T-win® di IO Biotech.
Gli studi preclinici hanno dimostrato che IO170 ha ridotto significativamente la crescita tumorale nei modelli di adenocarcinoma pancreatico e cancro alla prostata. Il vaccino ha indotto risposte immunitarie robuste e ha rimodellato il microambiente tumorale (TME) senza causare tossicità sistemica o effetti collaterali indesiderati. L'azienda si sta preparando per la presentazione di una Domanda di Nuovo Farmaco Sperimentale (IND) alla FDA per IO170.
IO Biotech (IOBT) presentó nuevos datos preclínicos para su novedala vacuna peptídica IO170 en la conferencia AACR-IO. La vacuna tiene como objetivo el Factor de Crecimiento Transformante Beta (TGF-β), un factor clave en la inmunosupresión de tumores sólidos. A diferencia de los enfoques existentes que inhiben el TGF-β de manera sistémica, IO170 modula selectivamente la actividad del TGF-β utilizando la plataforma propietaria T-win® de IO Biotech.
Los estudios preclínicos demostraron que IO170 redujo significativamente el crecimiento tumoral en modelos de adenocarcinoma pancreático y cáncer de próstata. La vacuna indujo respuestas inmunitarias robustas y remodeló el microambiente tumoral (TME) sin causar toxicidad sistémica ni efectos adversos fuera del objetivo. La empresa se está preparando para presentar una Solicitud de Nuevo Medicamento en Investigación (IND) a la FDA para IO170.
IO Biotech (IOBT)는 AACR-IO 회의에서 새로운 전임상 데이터를 발표했습니다. 이 혁신적인 펩타이드 백신 IO170은 고형 종양에서 주요 면역 억제 인자인 변형 성장 인자 베타(TGF-β)를 표적으로 합니다. 기존의 전신적으로 TGF-β를 억제하는 방법과 달리, IO170은 IO Biotech의 독점 T-win® 플랫폼을 사용하여 TGF-β의 활성을 선택적으로 조절합니다.
전임상 연구 결과, IO170은 췌장 선암 및 전립선암 모델에서 종양 성장을 유의미하게 감소시켰습니다. 이 백신은 강력한 면역 반응을 유도하고 종양 미세환경(TME)을 재구성했으며, 전신 독성이나 원하지 않는 오프 타겟 효과를 일으키지 않았습니다. 회사는 IO170을 위한 FDA에 대한 임상 시험 신약 신청(IND)을 준비하고 있습니다.
IO Biotech (IOBT) a présenté de nouvelles données précliniques pour son nouveau vaccin peptidique IO170 lors de la conférence AACR-IO. Le vaccin cible le Facteur de Croissance Transformant Beta (TGF-β), un facteur clé d'immunosuppression dans les tumeurs solides. Contrairement aux approches existantes qui inhibent le TGF-β de manière systémique, IO170 module sélectivement l'activité du TGF-β en utilisant la plateforme propriétaire T-win® d'IO Biotech.
Les études précliniques ont montré qu'IO170 réduisait significativement la croissance tumorale dans des modèles d'adénocarcinome pancréatique et de cancer de la prostate. Le vaccin a induit des réponses immunitaires robustes et a remodelé le microenvironnement tumoral (TME) sans provoquer de toxicité systémique ni d'effets indésirables hors cible. L'entreprise se prépare à soumettre une Demande de Nouveau Médicament d'Essai (IND) à la FDA pour IO170.
IO Biotech (IOBT) hat auf der AACR-IO-Konferenz neue präklinische Daten für seinen neuartigen Peptidimpfstoff IO170 vorgestellt. Der Impfstoff zielt auf den Transformierenden Wachstumsfaktor Beta (TGF-β), einen Schlüsselimmunsuppressor in soliden Tumoren. Im Gegensatz zu bestehenden Ansätzen, die TGF-β systemisch hemmen, moduliert IO170 selektiv die TGF-β-Aktivität mithilfe der proprietären T-win®-Plattform von IO Biotech.
Die präklinischen Studien zeigten, dass IO170 das Tumorwachstum in Modellen von Pankreasadenokarzinom und Prostatakrebs signifikant reduzierte. Der Impfstoff induzierte robuste Immunantworten und gestaltete das Tumormikroenvironment (TME) um, ohne systemische Toxizität oder unerwünschte Off-Target-Effekte zu verursachen. Das Unternehmen bereitet sich auf die Einreichung eines Antrags auf ein neues Prüfmedikament (IND) bei der FDA für IO170 vor.
- Preclinical data showed significant tumor growth reduction in multiple cancer models
- IO170 demonstrated effectiveness without systemic toxicity or adverse effects
- Company advancing toward FDA IND submission for IO170
- Product still in early preclinical stage
- No human trial data available yet
Insights
The preclinical data for IO170 represents a potentially significant breakthrough in cancer immunotherapy, particularly addressing a critical challenge in treating solid tumors. The targeting of TGF-β is especially noteworthy as this protein plays a central role in tumor immune evasion, but previous attempts at systemic inhibition have been by toxicity concerns.
The key differentiator here is IO Biotech's selective modulation approach through their T-win® platform. Rather than completely blocking TGF-β systemically, which can lead to serious side effects, their peptide vaccine specifically targets TGF-β+ cells within the tumor microenvironment. This selective approach could potentially overcome the safety limitations that have plagued other TGF-β targeting therapies while maintaining therapeutic efficacy.
The demonstration of efficacy in both pancreatic adenocarcinoma and prostate cancer models is particularly significant. Pancreatic cancer, with its 5-year survival rate below 10%, represents one of the most challenging oncology indications with treatment options. Similarly, advanced prostate cancer often develops resistance to existing therapies, creating a substantial market opportunity.
The progression toward an IND submission suggests confidence in the preclinical package and indicates potential clinical trials could begin within 12-18 months, assuming standard regulatory timelines. This positions IO Biotech to potentially expand its pipeline beyond its current lead programs, strengthening its market position in the competitive immuno-oncology space.
However, investors should note that while preclinical data is promising, the path to clinical validation remains long and complex. The true differentiation of IO170 from other immunotherapy approaches will only become clear in human trials, where factors such as immune response durability, combination potential, and real-world safety profile will be critical determinants of success.
• Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in solid tumors
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced details of its poster presentation at the American Association for Cancer Research (AACR)-IO conference taking place February 23-26, 2025, in Los Angeles, California.
Poster Presentation Details
Title: A TGF-β-directed peptide vaccine induces T cell activation & drives anti-tumor activity by modulating the architecture of the tumor microenvironment
Poster number: B117
Presenter: Matteo Bocci, PhD, Senior Scientist
Date and time: Tuesday, February 25, 2025, 1:45-4:00 PM PST
Location: JW Marriott Los Angeles, Platinum Ballroom A-E
Transforming Growth Factor Beta (TGF-β) is a key immune-suppressive factor in the tumor microenvironment (TME) of most solid tumors, often limiting the efficacy of various immune-oncology therapies. While global TGF-β inhibition strategies have shown limited success due to systemic toxicity, a more targeted modulation approach may be key to achieving sustained anti-tumor activity. IO Biotech’s proprietary T-win® platform is designed to selectively modulate TGF-β activity rather than fully inhibit it, targeting both tumor cells and key immune-suppressive cells within the TME.
The poster details the potential of IO170, a TGF-β peptide vaccine that showed significantly reduced tumor growth in pancreatic adenocarcinoma and prostate cancer models. The vaccine-induced robust immune responses reshaped the TME without causing systemic toxicity or adverse off-target effects. These findings support the continued development of an immune-modulatory vaccine targeting TGF-β as a novel approach for treating a wide range of cancers.
“Unlike other existing approaches that aim at inhibiting the TGFβ signaling systemically, our strategy uniquely targets TGFβ+ cells that are contributing to key immune resistance mechanisms in cancer,” said Ayako Wakatsuki Pedersen, PhD, Senior Vice President of Translational Research at IO Biotech. “These findings further validate our approach to immune-modulatory cancer vaccines that reshape the tumor microenvironment to enhance treatment efficacy. We look forward to advancing this research and sharing additional data as we explore its clinical applications while we prepare for an Investigational New Drug Application (IND) submission to FDA for IO170.”
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead investigational cancer vaccine candidate, Cylembio™ (imsapepimut and etimupepimut, adjuvanted) also known as IO102-IO103 in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Cylembio is a trademark of IO Biotech ApS.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing or outcome of primary analysis of the company’s Phase 3 trial, other current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Contact:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
Media
Julie Funesti
Edelman
917-498-1967
julie.funesti@edelman.com
FAQ
What are the key findings from IO Biotech's (IOBT) preclinical study of IO170?
How does IO Biotech's IO170 differ from existing TGF-β treatments?
What is the next regulatory step for IO Biotech's IO170 vaccine?
Which cancer types showed positive response to IO Biotech's IO170 in preclinical trials?
